Internet and Psychiatry
  • Home
    • Editorials
    • Research news
    • Research papers
    • Interviews with eminent psychiatrists
    • Ten years ago
    • Fifteen years ago
  • Topics
    • Alcohol and Drug Abuse
    • Anxiety Disorders
    • Biomedical Science
    • Compulsive gambling
    • Disaster Medicine
    • Education
    • General Medicine
      • Acupuncture
      • Physical medicine and Rehabilitation
    • Human Rights
    • Interviews with eminent psychiatrists
    • Mood Disorders
      • Bipolar Disorder
      • Depression
      • Seasonal Affective Disorder
    • Neurological Disorders
    • Other Psychiatric Disorders
    • Posttraumatic Stress Disorder
    • Sexual Behavior
  • Books
    • Comorbidity of Depression and Alcohol Use Disorders
    • “Immigration and Mental Health” chapter abstracts
    • “Internet and Suicide” chapter abstracts
    • “Neurobiology of PTSD” chapter abstracts
    • “Suicidal Behavior in Alcohol…” chapter abstracts
    • “Suicide in the Military” chapter abstracts
    • “Terror and Suicide” chapter abstracts
    • “War and Suicide” chapter abstracts
  • Editors
    • Leo Sher, M.D.
    • Alexander Vilens, M.S.
  • Guests
    • Distinguished Guests
    • Our Contributors
  • Reflections
    • Poetry
    • Quotes

Depression

Are Selective Serotonin Reuptake Inhibitors Safe for Drivers? What is the Evidence?

May 28, 2012

Ravera S, Ramaekers JG, de Jong-van den Berg LT, de Gier JJ.
Clin Ther. 2012 May 1. [Epub ahead of print]

Abstract
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are widely used medications to treat several psychiatric diseases and, above all, depression. They seem to be as effective as older antidepressants but have a different adverse effect profile. Despite their favorable safety profile, little is known about their influence on traffic safety.OBJECTIVE: To conduct a literature review to summarize the current evidence on the role of SSRIs in traffic safety, particularly concerning undesirable effects that could potentially impair fitness to drive, experimental and pharmacoepidemiologic studies on driving impairment, 2 existing categorization systems for driving-impairing medications, and the European legislative procedures for assessing fitness to drive before issuing a driver’s license and driving under the influence of medicines. METHODS: The article search was performed in the following electronic databases: MEDLINE, PsycINFO, ScienceDirect, and SafetyLit. The English-language scientific literature was searched using key words such as SSRIs and psychomotor performance, car crash or traffic accident, and adverse effects. For inclusion in this review, papers had to be full-text articles, refer to possible driving-related adverse effects, and be experimental or pharmacoepidemiologic studies on SSRIs and traffic accident risks. No restrictions concerning publication year were applied. RESULTS: Ten articles were selected as background information on driving-related adverse effects, and 15 articles were selected regarding experimental and pharmacoepidemiologic work. Regarding SSRI adverse effects, the most reported undesirable effects referring to driving impairment were anxiety, agitation, sleep disturbances, headache, increased risk of suicidal behavior, and deliberate self-harm. Regarding the remaining issues addressed in this article, inconsistencies were found between the outcomes of the selected experimental and epidemiologic studies and between the 2 existing categorization systems under evaluation. Some pitfalls of the current legislative scenario were identified as well. CONCLUSIONS: Based on the current evidence, it was concluded that more experimental and epidemiologic research is needed to elucidate the relationship between SSRI use and traffic safety. Furthermore, a revision of the existing categorization systems and harmonized European legislation in the field of medication use and driving were highly recommended.

Related Posts

Depression /

Suicidal behavior in a medical professional with comorbid depression and substance use disorder: an educational case report

Depression /

Combined dexamethasone suppression-corticotrophin-releasing hormone stimulation test in medication-free major depression and healthy volunteers

Depression /

Tolerability aspects in duloxetine-treated patients with depression: Should one use a lower starting dose in clinical practice?

‹ 42nd Annual Meeting of the International Society for Psychoneuroendocrinology › On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors

Editorials

  • Making space for pregnancy in compassionate use
  • COVID-19 and suicide
  • Pregnancy and COVID-19
  • Physician distress and relief during the coronavirus pandemic

Research Papers

  • Examination of depressive signs and symptoms among 803 University students in seven Universities and Colleges. Hungary, Romania, Serbia.
  • Examination of spirituality and the dimensions of spirituality among 803 students in seven different Universities. Hungary, Romania and Serbia.
  • Examination of depressive signs and symptoms among 932 students in eight different secondary schools in Hungary
  • Examination of psychological immune system among 932 students in eight different secondary schools in Hungary

Research News

  • Traumatic memory reactivation with or without propranolol for PTSD and comorbid major depression symptoms
  • COVID-19 prevalence and mortality among patients with schizophrenia
  • Bidirectional relations between COVID-19 and psychiatric disorders
  • Mental health problems among healthcare professionals during the COVID-19 crisis

Latest News

  • Suicide rates decreased in the United States
  • American Psychiatric Association Position Statement on Use of the Terms Client and Provider
  • Leading world experts on suicide. Expertscape, the January 31, 2021 report
  • Leading world experts on suicide. Expertscape, December 2020

Interviews with eminent psychiatrists

  • Interview with Professor Shih-Ku Lin
  • Interview with Professor Masahito Fushimi
  • Interview with Professor Maurizio Pompili
  • Interview with Professor Marco Sarchiapone

Ten Years Ago

  • Posttraumatic stress disorder and the Neuroevolutionary Time-depth Principle
  • The role of endogenous opioids and monoamine neurotransmitters in non-suicidal self-injury
  • The 2003 SARS outbreak and suicide among older adults
  • Objections to suicide among mood disordered patients with co-occurring alcohol use disorders

Back to Top

  • About
  • Contact
  • Privacy Policy
  • Terms and Conditions
Copyright © 2021 AVCalc LLC. All rights reserved worldwide.